Mechanistic description
Nanobodies engineered with pH-sensitive membrane fusion domains could selectively penetrate vesicles in acidic microenvironments around tau aggregates while remaining inactive in normal physiological pH environments.
Evidence for (5)
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids.
The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.
Evidence against (3)
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Synergy between amyloid-β and tau in Alzheimer's disease.
Cellular and pathological functions of tau.